<a href="https://www.fiercebiotech.com/biotech/novartis-sticks-2nd-deal-molecular-glue-biotech-orionis-worth-14b" hreflang="en">Novartis sticks 2nd deal with molecular glue biotech Orionis, this one worth up to $1.4B</a>
Novartis has signed a second collaboration deal with Orionis Biosciences, committing $40 million upfront and potentially up to $1.4 billion in milestone payments to develop therapeutics using Orionis' molecular glue technology. This partnership aims to target challenging therapeutic areas and follows a previous agreement established in 2020.
The most valuable insight for someone tracking biotech and healthtech is Novartis' continued investment in molecular glue technology through a significant $1.4 billion deal with Orionis Biosciences. This highlights the growing interest in AI-driven discovery platforms and molecular glues, indicating a potential lucrative area for investment and innovation in targeting challenging therapeutic targets across multiple disease areas.